Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia

Nature Clinical Practice Urology

Volumn 4, Issue 3, 2007, Pages 155-160

  Antunes, Alberto A ^a   Srougi, Miguel ^a   Coelho, Rafael F ^a   de Campos Freire, Geraldo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIBIOTIC AGENT; BOTULINUM TOXIN A; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; EPIDIDYMITIS; EVIDENCE BASED MEDICINE; FATIGUE; FECES INCONTINENCE; HUMAN; MICTURITION; NONHUMAN; ORGAN SIZE; ORTHOSTATIC HYPOTENSION; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SYMPTOMATOLOGY; URINARY TRACT DISEASE; URINE INCONTINENCE; URINE RETENTION; URINE VOLUME;

BOTULINUM TOXIN TYPE A; HUMANS; INJECTIONS, INTRALESIONAL; MALE; NEUROMUSCULAR AGENTS; PROSTATE; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY RETENTION; URODYNAMICS;

EID: 33947286360     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro0735     Document Type: Review

References (39)

1. Berry SJ et al. (1984) The development of human benign prostatic hyperplasia with age. J Urol 132: 474-479
2. Walsh PC (1996) Treatment of benign prostatic hyperplasia. N Engl J Med 335:586-587
3. Wei JT et al. (2005) Urologic diseases in America project: Benign prostatic hyperplasia. J Urol 173: 1256-1261
4. Welch G et al. (2002) Quality-of-life impact of lower urinary tract symptom severity: Results from the Health Professionals Follow-up Study. Urology 59:245-250
5. AUA Practice Guidelines Committee (2003) AUA guideline on management of benign prostatic hyperplasia. Chapter 1: Diagnosis and treatment recommendations. J Urol 170:530-547
6. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36:1-13
7. de la Rosette JJ et al. (2002) Long-term risk of retreatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol 167:1734-1739
8. Dmochowski R (2006) Antimuscarinic therapy in men with lower urinary tract symptoms: What is the evidence? Curr Urol Rep 7:462-467
9. Blake-James BT et al. (2007) The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 99: 85-96
10. Rassweiler J et al. (2006) Complications of transurethral resection of the prostate (TURP) - incidence, management, and prevention. Eur Urol 50: 969-980
11. Mishriki SF et al. (2006) Quality of life after TURP: Prospective 12 year follow up [abstract #1427]. J Urol 175 (Suppl): 461
12. McConnell JD et al. (1994) Benign prostatic hyperplasia: Diagnosis and treatment. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin 8:1-17
13. Thomas CA et al. (2006) Botulinum A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms. Curr Urol Rep 7:266-271
14. Kuo HC (2005) Prostate botulinum A toxin injection - an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 65:670-674
15. Cruz F and Silva C (2004) Botulinum toxin in the management of lower urinary tract dysfunction: Contemporary update. Curr Opin Urol 14:329-334
16. Smith CP and Chancellor MB (2004) Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 171:2128-2137
17. Aoki KR and Guyer B (2001) Botulinum toxin type A and other botulinum toxin serotypes: A comparative review of biochemical and pharmacological actions. Eur J Neurol 8 (Suppl 5): 21-29
18. DasGupta BR (1994) Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin. In Therapy with Botulinum Toxin, 15-39 (Eds Jankovic J and Hallen M) New York: Marcel Dekker
19. Scott AB and Suzuki D (1988) Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 3:333-335
20. Smith CP et al. (2003) Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 169:1896-1900
21. Argoff CE (2002) A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain 18 (Suppl): S177-S181
22. Cui M et al. (2004) Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107:125-133
23. Grazko MA et al. (1995) Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 45: 712-717
24. Kuo HC (2003) Effect of botulinum A toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology 61:550-554
25. Reitz A et al. (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510-515
26. Haferkamp A et al. (2004) Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 46:784-791
27. Chuang YC and Chancellor MB (2006) The application of botulinum toxin in the prostate. J Urol 176: 2375-2382
28. Shaari CM et al. (1995) Rhinorrhea is decreased in dogs after nasal application of botulinum toxin. Otolaryngol Head Neck Surg 112:566-571
29. Doggweiler R et al. (1998) Botox-induced prostatic involution. Prostate 37:44-50
30. Maria G et al. (2003) Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study. Urology 62:259-264
31. Chuang YC et al. (2005) Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 66:775-779
32. Chuang YC et al. (2006) Beneficial effects of up to one year with intraprostatic botulinum toxin type A injection on LUTS and quality of life in BPH patients [abstract #1436]. J Urol 175 (Suppl): 464
33. Ventura S et al. (2002) Cholinergic innervation and function in the prostate gland. Pharmacol Ther 94: 93-112
34. Higgins JR and Gosling JA (1989) Studies on the structure and intrinsic innervation of the normal human prostate. Prostate Suppl 2:5-16
35. Lepor H and Kuhar MJ (1984) Characterization and localization of the muscarinic cholinergic receptor in human prostatic tissue. J Urol 132:397-402
36. Chuang YC et al. (2006) Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol 175:1158-1163
37. Larson TR et al. (2005) Intraprostatic injection of botulinum toxin in the treatment of symptomatic LUTS, including sequential MRIS for accurate changes in size of the prostate. J Urol 173:376-377
38. Guercini F et al. (2005) Intraprostatic botulin toxin injection in patients with severe benign prostatic hyperplasia: A multicenter feasibility study [abstract #1387]. J Urol 173 (Suppl): 376
39. Smith CP et al. (2003) Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 169:1896-1900